Effects of the PDE5-inhibitor vardenafil in a mouse stroke model

Brain Research

Volumn 1265, Issue , 2009, Pages 148-157

  Royl, Georg ^a   Balkaya, Mustafa ^a   Lehmann, Sabrina ^a   Lehnardt, Seija ^a   Stohlmann, Katharina ^a   Lindauer, Ute ^a,b   Endres, Matthias ^a   Dirnagl, Ulrich ^a   Meisel, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cerebral blood flow; Cerebral ischemia; CNS regeneration; High field MRI; Mouse; Phosphodiesterase V

Indexed keywords

EOSIN; HEMATOXYLIN; PHOSPHODIESTERASE V INHIBITOR; VARDENAFIL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; BODY WEIGHT; BRAIN ARTERY; BRAIN ATROPHY; CONTROL GROUP; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MOUSE; FROZEN SECTION; IMMUNOHISTOCHEMISTRY; MIDDLE CEREBRAL ARTERY; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SHAM PROCEDURE; STROKE; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; BRAIN; CEREBROVASCULAR CIRCULATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DEPRESSION; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; GLIAL FIBRILLARY ACIDIC PROTEIN; IMIDAZOLES; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RECOVERY OF FUNCTION; STROKE; SULFONES; TREATMENT OUTCOME; TRIAZINES;

ANIMALIA; MURINAE; MUS; RODENTIA;

EID: 62949220187     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.01.061     Document Type: Article

References (28)

1. Aberson C. Interpreting NULL results. JASNH 1 (2002) 36-42
2. Craft T.K., and DeVries A.C. Role of IL-1 in poststroke depressive-like behavior in mice. Biol. Psychiatry 60 (2006) 812-818
3. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 26 (2006) 1465-1478
4. Filippi S., Morelli A., Sandner P., Fibbi B., Mancina R., Marini M., Gacci M., Vignozzi L., Vannelli G.B., Carini M., Forti G., and Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148 (2007) 1019-1029
5. Gao F., Sugita M., and Nukui H. Phosphodiesterase 5 inhibitor, zaprinast, selectively increases cerebral blood flow in the ischemic penumbra in the rat brain. Neurol. Res. 27 (2005) 638-643
6. Gertz K., Priller J., Kronenberg G., Fink K.B., Winter B., Schrock H., Ji S., Milosevic M., Harms C., Bohm M., Dirnagl U., Laufs U., and Endres M. Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ. Res. 99 (2006) 1132-1140
7. Hohenstein B., Daniel C., Wittmann S., and Hugo C. PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol. Dial. Transplant. 23 (2008) 3427-3436
8. Korpi E.R., Koikkalainen P., Vekovischeva O.Y., Makela R., Kleinz R., Uusi-Oukari M., and Wisden W. Cerebellar granule-cell-specific GABAA receptors attenuate benzodiazepine-induced ataxia: evidence from alpha 6-subunit-deficient mice. Eur. J. Neurosci. 11 (1999) 233-240
9. Kruuse C., Thomsen L.L., Jacobsen T.B., and Olesen J. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J. Cereb. Blood Flow Metab. 22 (2002) 1124-1131
10. Kruuse C., Thomsen L.L., Birk S., and Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126 (2003) 241-247
11. Lehnardt S., Lehmann S., Kaul D., Tschimmel K., Hoffmann O., Cho S., Krueger C., Nitsch R., Meisel A., and Weber J.R. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J. Neuroimmunol. 190 (2007) 28-33
12. Leithner C., Gertz K., Schrock H., Priller J., Prass K., Steinbrink J., Villringer A., Endres M., Lindauer U., Dirnagl U., and Royl G. A flow sensitive alternating inversion recovery (FAIR)-MRI protocol to measure hemispheric cerebral blood flow in a mouse stroke model. Exp. Neurol. 210 (2008) 118-127
13. Li L., Jiang Q., Zhang L., Ding G., Gang Z.Z., Li Q., Ewing J.R., Lu M., Panda S., Ledbetter K.A., Whitton P.A., and Chopp M. Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res. 1132 (2007) 185-192
14. Lubamba B., Lecourt H., Lebacq J., Lebecque P., De Jonge H., Wallemacq P., and Leal T. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am. J. Respir. Crit. Care Med. 177 (2008) 506-515
15. Matsuura K., Kabuto H., Makino H., and Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73 (1997) 45-48
16. Meisel C., Prass K., Braun J., Victorov I., Wolf T., Megow D., Halle E., Volk H.D., Dirnagl U., and Meisel A. Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke 35 (2004) 2-6
17. Mergenthaler P., Dirnagl U., and Meisel A. Pathophysiology of stroke: lessons from animal models. Metab. Brain Dis. 19 (2004) 151-167
18. Ogawa N., Hirose Y., Ohara S., Ono T., and Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50 (1985) 435-441
19. Prass K., Meisel C., Hoflich C., Braun J., Halle E., Wolf T., Ruscher K., Victorov I.V., Priller J., Dirnagl U., Volk H.D., and Meisel A. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J. Exp. Med. 198 (2003) 725-736
20. Prass K., Scharff A., Ruscher K., Lowl D., Muselmann C., Victorov I., Kapinya K., Dirnagl U., and Meisel A. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34 (2003) 1981-1986
21. Prass K., Royl G., Lindauer U., Freyer D., Megow D., Dirnagl U., Stockler-Ipsiroglu G., Wallimann T., and Priller J. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow Metab. 27 (2007) 452-459
22. Prüss H., Prass K., Ghaeni L., Milosevic M., Muselmann C., Freyer D., Royl G., Reuter U., Baeva N., Dirnagl U., Meisel A., and Priller J. Inducible nitric oxide synthase does not mediate brain damage after transient focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 28 (2008) 526-539
23. Tinel H., Stelte-Ludwig B., Hutter J., and Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 98 (2006) 1259-1263
24. Winter B., Juckel G., Viktorov I., Katchanov J., Gietz A., Sohr R., Balkaya M., Hortnagl H., and Endres M. Anxious and hyperactive phenotype following brief ischemic episodes in mice. Biol. Psychiatry 57 (2005) 1166-1175
25. Zhang R., Wang Y., Zhang L., Zhang Z., Tsang W., Lu M., Zhang L., and Chopp M. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33 (2002) 2675-2680
26. Zhang R., Wang L., Zhang L., Chen J., Zhu Z., Zhang Z., and Chopp M. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ. Res. 92 (2003) 308-313
27. Zhang L., Zhang R.L., Wang Y., Zhang C., Zhang Z.G., Meng H., and Chopp M. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 36 (2005) 847-852
28. Zhang L., Zhang Z., Zhang R.L., Cui Y., LaPointe M.C., Silver B., and Chopp M. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 1118 (2006) 192-198